IL209622A0 - Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators - Google Patents

Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators

Info

Publication number
IL209622A0
IL209622A0 IL209622A IL20962210A IL209622A0 IL 209622 A0 IL209622 A0 IL 209622A0 IL 209622 A IL209622 A IL 209622A IL 20962210 A IL20962210 A IL 20962210A IL 209622 A0 IL209622 A0 IL 209622A0
Authority
IL
Israel
Prior art keywords
glutamate receptor
metabotropic glutamate
isoxazole derivatives
receptor potentiators
potentiators
Prior art date
Application number
IL209622A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Joseph Cacciola
James Empfield
James Folmer
Angela M Hunter
Scott Throner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Joseph Cacciola, James Empfield, James Folmer, Angela M Hunter, Scott Throner filed Critical Astrazeneca Ab
Publication of IL209622A0 publication Critical patent/IL209622A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/08Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/083Clips, e.g. resilient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/08Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/085Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound with adhesive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/10Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/10Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • A61B17/105Wound clamp magazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL209622A 2008-06-06 2010-11-29 Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators IL209622A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5948508P 2008-06-06 2008-06-06
PCT/SE2009/050682 WO2009148403A1 (en) 2008-06-06 2009-06-08 Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators

Publications (1)

Publication Number Publication Date
IL209622A0 true IL209622A0 (en) 2011-02-28

Family

ID=41398335

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209622A IL209622A0 (en) 2008-06-06 2010-11-29 Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators

Country Status (40)

Country Link
US (4) US7790760B2 (enExample)
EP (2) EP2303872B1 (enExample)
JP (2) JP5476371B2 (enExample)
KR (1) KR20110020797A (enExample)
CN (1) CN102105466B (enExample)
AR (1) AR072016A1 (enExample)
AU (1) AU2009255784B2 (enExample)
BR (1) BRPI0913585A2 (enExample)
CA (1) CA2726925A1 (enExample)
CL (1) CL2010001348A1 (enExample)
CO (1) CO6321239A2 (enExample)
CR (1) CR11826A (enExample)
CU (1) CU23883B1 (enExample)
CY (1) CY1115301T1 (enExample)
DK (1) DK2303872T3 (enExample)
DO (1) DOP2010000375A (enExample)
EA (2) EA201300342A1 (enExample)
EC (1) ECSP10010662A (enExample)
ES (1) ES2469837T3 (enExample)
GT (1) GT201000342A (enExample)
HK (1) HK1201255A1 (enExample)
HN (1) HN2010002582A (enExample)
HR (1) HRP20140451T1 (enExample)
IL (1) IL209622A0 (enExample)
MX (1) MX2010012949A (enExample)
MY (1) MY156552A (enExample)
NI (3) NI201000209A (enExample)
NZ (1) NZ590344A (enExample)
PE (1) PE20110028A1 (enExample)
PL (1) PL2303872T3 (enExample)
PT (1) PT2303872E (enExample)
RS (1) RS53392B (enExample)
SA (1) SA109300358B1 (enExample)
SI (1) SI2303872T1 (enExample)
SV (1) SV2010003751A (enExample)
TW (3) TW201514173A (enExample)
UA (1) UA107649C2 (enExample)
UY (1) UY31870A (enExample)
WO (1) WO2009148403A1 (enExample)
ZA (1) ZA201008611B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
WO2009033703A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
TWI475995B (zh) 2007-09-14 2015-03-11 詹森藥物公司 1’,3’-二取代-4-苯基-3,4,5,6-四氫-2h,1’h-〔1,4’〕聯吡啶基-2’-酮化物
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
MX2011002042A (es) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
MX2011003691A (es) 2008-10-16 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
AR076859A1 (es) 2009-05-12 2011-07-13 Ortho Mcneil Janssen Pharm Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN109999025A (zh) 2014-01-21 2019-07-12 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
US10099993B2 (en) 2014-04-06 2018-10-16 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof
KR101663662B1 (ko) * 2015-06-17 2016-10-14 한국과학기술연구원 대사성 글루타메이트 수용체 1에 활성을 지닌 신규 아릴 아이소옥사졸 유도체
WO2017089892A1 (en) * 2015-11-25 2017-06-01 Astrazeneca Ab Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. Derive de 3-methylenisoindolin-1-one
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
US6017919A (en) * 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
AU7548298A (en) 1997-05-30 1998-12-30 Meiji Seika Kaisha Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
CA2311131A1 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
CA2401711C (en) * 2000-02-29 2008-06-03 Mitsubishi Pharma Corporation Cyclic amide derivatives
BR0112856A (pt) 2000-07-31 2003-07-01 Smithkline Beecham Plc Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos
PL368129A1 (en) 2001-08-09 2005-03-21 Ono Pharmaceutical Co, Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
CA2519954A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
US20070135485A1 (en) 2003-10-22 2007-06-14 Gillig James R Novel mch receptor antagonists
WO2005074643A2 (en) 2004-01-30 2005-08-18 Smithkline Beecham Corporation Benzamide compounds useful as rock inhibitors
JP2007523183A (ja) 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ 縮合複素環式化合物及び代謝調節型グルタミン酸受容体アンタゴニストとしてのその使用
KR101197482B1 (ko) 2004-03-05 2012-11-09 닛산 가가쿠 고교 가부시키 가이샤 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제
CA2558278A1 (en) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. Diaryl-substituted five-membered heterocycle derivative
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
JP2008517920A (ja) 2004-10-25 2008-05-29 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体の複素環式インダノン増強因子
AU2006216917A1 (en) 2005-02-24 2006-08-31 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
EP1893606A2 (en) 2005-05-18 2008-03-05 Addex Pharma SA Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
EP1912939A1 (en) * 2005-08-12 2008-04-23 AstraZeneca AB Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
BRPI0616571A2 (pt) 2005-09-27 2011-06-21 Hoffmann La Roche oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286

Also Published As

Publication number Publication date
SI2303872T1 (sl) 2014-06-30
AU2009255784B2 (en) 2012-08-16
AU2009255784A1 (en) 2009-12-10
US7790760B2 (en) 2010-09-07
UY31870A (es) 2010-01-29
US7781434B2 (en) 2010-08-24
ECSP10010662A (es) 2011-01-31
TWI382027B (zh) 2013-01-11
UA107649C2 (uk) 2015-02-10
NI201002092A (es) 2012-11-07
JP5476371B2 (ja) 2014-04-23
NZ590344A (en) 2012-07-27
US8148372B2 (en) 2012-04-03
CN102105466A (zh) 2011-06-22
HN2010002582A (es) 2012-08-27
AR072016A1 (es) 2010-07-28
EA018412B1 (ru) 2013-07-30
US20100324044A1 (en) 2010-12-23
EA201300342A1 (ru) 2014-02-28
US20100022545A1 (en) 2010-01-28
EP2303872B1 (en) 2014-04-16
EP2303872A1 (en) 2011-04-06
WO2009148403A1 (en) 2009-12-10
BRPI0913585A2 (pt) 2015-10-27
NI201002091A (es) 2012-11-07
JP2011522816A (ja) 2011-08-04
JP2014114312A (ja) 2014-06-26
DK2303872T3 (da) 2014-06-16
JP5815765B2 (ja) 2015-11-17
TW201247658A (en) 2012-12-01
EP2303872A4 (en) 2012-03-21
CY1115301T1 (el) 2017-01-04
CU20100238A7 (es) 2011-11-15
EA201001724A1 (ru) 2011-08-30
TW201002699A (en) 2010-01-16
HRP20140451T1 (hr) 2014-08-01
CN102105466B (zh) 2014-10-15
US20100317662A1 (en) 2010-12-16
HK1201255A1 (en) 2015-08-28
CA2726925A1 (en) 2009-12-10
DOP2010000375A (es) 2010-12-31
PE20110028A1 (es) 2011-02-11
ZA201008611B (en) 2012-05-30
TWI477499B (zh) 2015-03-21
SV2010003751A (es) 2011-04-14
MX2010012949A (es) 2010-12-15
TW201514173A (zh) 2015-04-16
CL2010001348A1 (es) 2011-03-25
NI201000209A (es) 2012-11-07
EP2772492B1 (en) 2016-08-17
CR11826A (es) 2011-02-04
EP2772492A1 (en) 2014-09-03
MY156552A (en) 2016-02-26
HK1155744A1 (en) 2012-05-25
ES2469837T3 (es) 2014-06-20
PL2303872T3 (pl) 2014-08-29
RS53392B (sr) 2014-10-31
KR20110020797A (ko) 2011-03-03
PT2303872E (pt) 2014-06-23
CU23883B1 (es) 2013-04-19
GT201000342A (es) 2015-02-16
US20090306158A1 (en) 2009-12-10
SA109300358B1 (ar) 2012-11-03
US7888353B2 (en) 2011-02-15
CO6321239A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
IL209622A0 (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
HRP20150210T1 (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor -842 potentiators
EP2167501A4 (en) OXADIAZOLE LIGANDS FROM METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE AS POTENTIALIZERS - 841
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
IL205176A0 (en) Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
IL210412A0 (en) Heterocyclic derivatives and uses thereof
IL219309A0 (en) Glycoside derivatives and uses thereof
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
IL210834A0 (en) Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
IL201202A0 (en) Imidazolidine carboxamide derivatives as p2x7 modulators
PL2470499T3 (pl) Nowe pochodne kolchicyny, sposoby i ich zastosowania
IL208771A0 (en) Iminopyridine derivatives and use thereof
EP2285778A4 (en) NIKOTINAMIDDERIVATE
ZA201104354B (en) Rock anchor
EP2442649A4 (en) USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIALIZERS TO REDUCE NICOTINE DEPENDENCE
EP2274294A4 (en) 5-DIMETHOXY FUMAGILLOL AND ITS DERIVATIVES
IL206951A0 (en) 3-alkyl-piperazine derivatives and uses thereof
ZA201203631B (en) New phenylhydrazone derivatives and their use as pharmaceuticals
HK1137021A (en) Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
HK1130492A (en) Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
IL206950A0 (en) Aminopiperidinyl derivatives and uses thereof
HK1142609A (en) Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators - 841
HK1155721A (en) Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
HK1167385A (en) Thiazole derivatives and their use as p2y12 receptor antagonists